Just got off the phone with two different individu

Just got off the phone with two different individuals who work for the FDA. Call them yourself if you don’t believe me I have the number.

They could not disclose if the clinical hold was lifted. They specifically stated that it’s up to the company to disclose that information. I was very specific with my questions and both said the same thing.

One lady on the phone basically said she was aware of Leronlimabs hold on covid and that it is rare for the FDA to make a public statement. The other lady had to look up the information.

So Craig you are wrong the FDA can’t disclose it, it is up to the company to disclose that information. So it’s is completely possible the hold has been lifted and they did not PR it for whatever reason. They could also be working on protocol of the trial during and after the hold. I didn’t get into detail there.

For further information about it you would have to call Cytodyn or FOIA request the information.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009

(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech

Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025

FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy


— Jeremiah 51:36